Get the Stockscreener App
0.6832
1.74%
-0.0121
After Hours:
.69
0.0068
+1.00%
Tenaya Therapeutics Inc stock is traded at $0.6832, with a volume of 1.19M.
It is down -1.74% in the last 24 hours and down -7.87% over the past month.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
See More
Previous Close:
$0.6953
Open:
$0.69
24h Volume:
1.19M
Relative Volume:
0.53
Market Cap:
$153.19M
Revenue:
-
Net Income/Loss:
$-83.01M
P/E Ratio:
-1.4499
EPS:
-0.4712
Net Cash Flow:
$-64.63M
1W Performance:
-1.00%
1M Performance:
-7.87%
6M Performance:
+17.51%
1Y Performance:
-44.90%
1-Day Range:
$0.6811
$0.7096
1-Week Range:
$0.672
$0.7101
52-Week Range:
$0.5316
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.6832 | 154.83M | 0 | -83.01M | -64.63M | -0.4712 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
A heart-disease biotech will meet investors at two September conferences - Stock Titan
Israel Englander group takes passive stake in Tenaya Therapeutics (TNYA) - Stock Titan
Tenaya Therapeutics (TNYA) Falls 3.85% to $0.70 as Shares Approach Critical SupportSynthetic Long - vinanet.vn
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301 - MarketBeat
Tenaya therapeutics CEO Ali Faraz sells $15.8k in company shares By Investing.com - Investing.com Australia
Tenaya therapeutics CMO Tingley Whittemore sells $5,267 in stock By Investing.com - Investing.com Nigeria
Tenaya therapeutics CEO Ali Faraz sells $15.8k in company shares - Investing.com
Tenaya therapeutics CMO Tingley Whittemore sells $5,267 in stock - Investing.com
Tenaya Therapeutics (NASDAQ:TNYA) CEO Sells $15,784.72 in Stock - MarketBeat
Tenaya Therapeutics, Inc. SEC Filing (Aug 18, 2026) - Stock Titan
GSA Capital Partners LLP Makes New $1.97 Million Investment in Tenaya Therapeutics, Inc. $TNYA - MarketBeat
Tenaya Therapeutics (TNYA) Q2 2026 Earnings: EPS Misses by 186.94% as Clinical-Stage Pipeline Drives Wider-Than-Expected LossRevenue Recognition Risk - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Transcript : Tenaya Therapeutics, Inc. Presents at Canaccord Genuity's 46th Annual Growth Conference, Aug-11-2026 12 - marketscreener.com
Tenaya Therapeutics (TNYA) Institutional Ownership 2026 - MarketBeat
Tenaya Therapeutics (TNYA) Drops 4% to $0.73 — Testing Crucial Support ZoneADD Alert - Vinanet
TNYA Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Climb on Pipeline OptimismDiluted EPS Report - Vinanet
Tenaya Therapeutics (TNYA) Rises 1.89% to $0.75, Holding Above $0.71 SupportIndex Put Call - vinanet.vn
Tenaya Therapeutics at Canaccord Genuity conference: q4 catalysts loom By Investing.com - Investing.com Canada
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Renaissance Technologies LLC Increases Stock Holdings in Tenaya Therapeutics, Inc. $TNYA - MarketBeat
HC Wainwright Has Positive Outlook of TNYA FY2026 Earnings - MarketBeat
Q3 Earnings Forecast for TNYA Issued By HC Wainwright - MarketBeat
H.C. Wainwright Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
William Blair Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating - moomoo.com
Tenaya Therapeutics (NASDAQ:TNYA) Issues Quarterly Earnings Results - MarketBeat
Tenaya Therapeutics (TNYA) Gains 5.81% as Biotech Stock Holds Above Critical $0.74 SupportZero Gamma Level - dars.gov.et
Tenaya Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Tenaya Therapeutics Q2 net loss widens on impairment charge - TradingView
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Tenaya Therapeutics (TNYA) to Post Earnings on Wednesday - MarketBeat
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Tenaya CFO Eric Hyllengren to Speak at Boston Conference - Stock Titan
Tenaya Therapeutics (TNYA) Slips to $0.74 as Key Support at $0.70 Comes into FocusAAII Neutral - vinanet.vn
Tenaya Therapeutics Inc (TNYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tenaya Therapeutics Inc (TNYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
TNYA|Tenaya Therapeutics Inc|Price:0.769|Chg%:-0.006 - TradingKey
Tenaya Therapeutics Inc (TNYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tenaya Therapeutics Inc (TNYA) Cash Flow - TradingKey
Tenaya Therapeutics, Inc. Revenue Breakdown – NASDAQ:TNYA - TradingView
Tenaya Therapeutics Inc (TNYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tenaya Therapeutics Inc (TNYA) Institutional Confidence - TradingKey
Tenaya Therapeutics (TNYA) Holds Near Support as Micro-Cap Biotech Seeks DirectionPut Support - vinanet.vn
Tenaya Therapeutics (TNYA) Edges Higher Amid Consolidation Near SupportThrowback Trade - vinanet.vn
Tenaya Therapeutics Q1 2026 Earnings: Slight EPS Miss as Pre-Revenue Biotech Advances Heart Disease Pipeline - dars.gov.et
Tenaya Therapeutics Inc. (TNYA) Q1 2026 Earnings: EPS Slightly Misses Estimates, Stock Declines as Pre-Revenue Biotech Continues Pipeline DevelopmentRevenue Per Share - dars.gov.et
Tenaya’s new CFO gets options on 1.65M shares, with a $0.8365 exercise price - Stock Titan
Tenaya Therapeutics (TNYA) CFO files first Form 3 ownership report - Stock Titan
Tenaya Therapeutics (TNYA) grants CFO 1,650,000 stock options - Stock Titan
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Tenaya Therapeutics (TNYA) Slides to $0.86 as Bearish Pressure Tests SupportMomentum ETF - vinanet.vn
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tenaya Therapeutics Inc Stock (TNYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tingley Whittemore | Chief Medical Officer |
Aug 17 '26 |
Sale |
0.71 |
7,424 |
5,270 |
214,073 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):